T1	Participants 447 551	Eligible patients were treatment naive, and had stage IIIA and B unresectable non-small-cell lung cancer
T2	Participants 892 1013	total of 388 patients were needed to detect a 50% increase in median survival from 14 months of qdRT to 21 months of HART
T3	Participants 1085 1187	141 patients enrolled, 83% were randomly assigned after chemotherapy to qdRT (n = 59) or HART (n = 60)
T4	Participants 1440 1561	Grade > or = 3 toxicities included esophagitis in 14 v nine patients, and pneumonitis in 0 v 6 patients for HART and qdRT
